The second study (NCT03977467, phase II) assesses the efficacy and safety of combining atezolizumab with standard-of-care chemotherapy in non-small cell lung cancer (NSCLC) and atezolizumab combined with tiragolumab in patients with advanced solid tumors who have progressed after prior exposure to anti-PD-1 or anti-PD-L1 treatment. Here, CD274 is linked to non-small cell lung carcinoma.